Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Deckers Outdoor Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.68 (market cap $4.49B), while Deckers Outdoor Corp trades at $101.22 (market cap $14.73B). The key difference: Deckers Outdoor Corp is far larger — about 3.3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| ACAD | DECK | |
|---|---|---|
Market Cap | $4.49B | $14.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $123.91 |
52-Week Low | $20.06 | $79.54 |
Enterprise Value | $3.69B | $13.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Deckers Outdoor Corp (DECK) trades at $106.08, up 1.33% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.99B in 2025, with net income reaching $966M and a robust ROE of 40.86%. Recent quarters show consistent earnings beats, and analyst consensus targets $121.50. The stock benefits from international expansion of UGG and HOKA brands, as highlighted by Zacks Investment Research on 2026-07-01.
The outlook for DECK is positive, supported by earnings momentum and global growth initiatives, but risks include competitive pressures and market volatility. With a P/E of 15.05, the stock appears reasonably valued, offering potential upside to the consensus target. Investors should weigh strong profitability against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
